Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Mizuho from $109.00 to $106.00. They now have a "buy" rating on the stock.
Axsome Therapeutics to Present at Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target lowered by analysts at Citigroup Inc. from $127.00 to $125.00. They now have a "buy" rating on the stock.